DGAP-News

German medical technology company avateramedical N.V. appoints Ian Read, former Chairman and CEO of Pfizer, to the Board

DGAP-News: avateramedical GmbH / Key word(s): Personnel German medical technology company avateramedical N.V. appoints Ian Read, former Chairman and CEO of Pfizer, to the Board 24.09.2020 / 10:00 The issuer is solely responsible for the content of this announcement. German medical technology company avateramedical N.V. appoints Ian Read, former Chairman and CEO of Pfizer, to the Board

Amsterdam, The Netherlands / Jena, Germany, September 24, 2020 - avateramedical N.V., parent company of avateramedical GmbH, an innovative German medical technology company specializing in robot-assisted, minimally invasive surgery, this week announced the appointment of Ian Read as member of the Supervisory Board by the Annual General Meeting. The AGM voted in favor of all resolutions.

Joseph M. Hogan, Chairman of avateramedical N.V., commented: "We officially welcome Ian Read to our Supervisory Board. Ian, who is a member of the Advisory Board of Tennor Holding N.V., represents our main shareholder and is a great addition to our Board following his extraordinary career, over four decades, in the global healthcare industry and principally with Pfizer, one of the world's largest pharmaceutical companies. Ian stands for good governance, growth and value creation and the ability to transform companies to become strong and successful market leaders."

As former president, Chief Executive Officer, and Chairman of Pfizer Mr Read created more than $240 billion of shareholder value. Mr Read was appointed Pfizer's CEO in 2010, and a year later, became Chairman of the board. He retired as CEO in December 2018 and as board Chairman at the end of 2019. He is presently Chairman of DXC, a board member of Kimberly-Clark Corporation and he serves as an Operating Executive in the Global Healthcare Group for the Carlyle Group. Mr Read will join the board of directors of new company Viatris upon the completion of the merger between Mylan N.V. and Upjohn Inc., which received shareholder approval in late June 2020.